Now showing items 1-20 of 22

    • Acquiring evidence for precision prostate cancer care. 

      Mateo, J; Carreira, S; de Bono, JS (2017-05-01)
    • Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. 

      Sharp, A; Coleman, I; Yuan, W; Sprenger, C; Dolling, D; Rodrigues, DN; Russo, JW; Figueiredo, I; Bertan, C; Seed, G; Riisnaes, R; Uo, T; Neeb, A; Welti, J; Morrissey, C; Carreira, S; Luo, J; Nelson, PS; Balk, SP; True, LD; de Bono, JS; Plymate, SR (2019-01-02)
      BACKGROUND: Liquid biopsies have demonstrated that the constitutively active androgen receptor splice variant-7 (AR-V7) associates with reduced response and overall survival from endocrine therapies in castration-resistant ...
    • Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. 

      Sundar, R; Miranda, S; Rodrigues, DN; Chénard-Poirier, M; Dolling, D; Clarke, M; Figueiredo, I; Bertan, C; Yuan, W; Ferreira, A; Chistova, R; Boysen, G; Perez, DR; Tunariu, N; Mateo, J; Wotherspoon, A; Chau, I; Cunningham, D; Valeri, N; Carreira, S; de Bono, J (2018-12)
      BACKGROUND: Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM ...
    • Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. 

      Puglisi, M; Stewart, A; Thavasu, P; Frow, M; Carreira, S; Minchom, A; Punwani, R; Bhosle, J; Popat, S; Ratoff, J; de Bono, J; Yap, TA; O''Brien, M; Banerji, U (2016-01)
      We hypothesised that it was possible to quantify phosphorylation of important nodes in the phosphatidylinositol 3-kinase (PI3K) pathway in cancer cells isolated from pleural effusions of patients with non-small cell lung ...
    • Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. 

      Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; Miranda, S; Perez-Lopez, R; Dolling, D; Robinson, DR; Sandhu, S; Fowler, G; Ebbs, B; Flohr, P; Seed, G; Rodrigues, DN; Boysen, G; Bertan, C; Atkin, M; Clarke, M; Crespo, M; Figueiredo, I; Riisnaes, R; Sumanasuriya, S; Rescigno, P; Zafeiriou, Z; Sharp, A; Tunariu, N; Bianchini, D; Gillman, A; Lord, CJ; Hall, E; Chinnaiyan, AM; Carreira, S; de Bono, JS; TOPARP-A investigators (2017-09)
      Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity ...
    • Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. 

      Mateo, J; Cheng, HH; Beltran, H; Dolling, D; Xu, W; Pritchard, CC; Mossop, H; Rescigno, P; Perez-Lopez, R; Sailer, V; Kolinsky, M; Balasopoulou, A; Bertan, C; Nanus, DM; Tagawa, ST; Thorne, H; Montgomery, B; Carreira, S; Sandhu, S; Rubin, MA; Nelson, PS; de Bono, JS (2018-05)
      BACKGROUND: Germline DNA damage repair gene mutation (gDDRm) is found in >10% of metastatic prostate cancer (mPC). Their prognostic and predictive impact relating to standard therapies is unclear. OBJECTIVE: To determine ...
    • Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. 

      Sharp, A; Welti, JC; Lambros, MBK; Dolling, D; Rodrigues, DN; Pope, L; Aversa, C; Figueiredo, I; Fraser, J; Ahmad, Z; Lu, C; Rescigno, P; Kolinsky, M; Bertan, C; Seed, G; Riisnaes, R; Miranda, S; Crespo, M; Pereira, R; Ferreira, A; Fowler, G; Ebbs, B; Flohr, P; Neeb, A; Bianchini, D; Petremolo, A; Sumanasuriya, S; Paschalis, A; Mateo, J; Tunariu, N; Yuan, W; Carreira, S; Plymate, SR; Luo, J; de Bono, JS (2019-04-27)
      BACKGROUND: Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant prostate cancer (mCRPC). However, studies ...
    • Detection of circulating tumour cell clusters in human glioblastoma. 

      Krol, I; Castro-Giner, F; Maurer, M; Gkountela, S; Szczerba, BM; Scherrer, R; Coleman, N; Carreira, S; Bachmann, F; Anderson, S; Engelhardt, M; Lane, H; Evans, TRJ; Plummer, R; Kristeleit, R; Lopez, J; Aceto, N (2018-08)
      Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating tumour cells (CTCs) are sporadically found in GBM patients, yet it is unclear whether multicellular ...
    • Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. 

      Stewart, A; Coker, EA; Pölsterl, S; Georgiou, A; Minchom, AR; Carreira, S; Cunningham, D; O'Brien, ME; Raynaud, FI; de Bono, JS; Al-Lazikani, B; Banerji, U (2019-08)
      It is increasingly appreciated that drug response to different cancers driven by the same oncogene is different and may relate to differences in rewiring of signal transduction. We aimed to study differences in dynamic ...
    • Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. 

      Seed, G; Yuan, W; Mateo, J; Carreira, S; Bertan, C; Lambros, M; Boysen, G; Ferraldeschi, R; Miranda, S; Figueiredo, I; Riisnaes, R; Crespo, M; Rodrigues, DN; Talevich, E; Robinson, DR; Kunju, LP; Wu, Y-M; Lonigro, R; Sandhu, S; Chinnaiyan, AM; de Bono, JS (2017-10-15)
      Purpose: Precise detection of copy number aberrations (CNA) from tumor biopsies is critically important to the treatment of metastatic prostate cancer. The use of targeted panel next-generation sequencing (NGS) is inexpensive, ...
    • Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. 

      Zafeiriou, Z; Bianchini, D; Chandler, R; Rescigno, P; Yuan, W; Carreira, S; Barrero, M; Petremolo, A; Miranda, S; Riisnaes, R; Rodrigues, DN; Gurel, B; Sumanasuriya, S; Paschalis, A; Sharp, A; Mateo, J; Tunariu, N; Chinnaiyan, AM; Pritchard, CC; Kelly, K; de Bono, JS (2019-01)
      Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, ...
    • Genomic correlates of clinical outcome in advanced prostate cancer. 

      Abida, W; Cyrta, J; Heller, G; Prandi, D; Armenia, J; Coleman, I; Cieslik, M; Benelli, M; Robinson, D; Van Allen, EM; Sboner, A; Fedrizzi, T; Mosquera, JM; Robinson, BD; De Sarkar, N; Kunju, LP; Tomlins, S; Wu, YM; Nava Rodrigues, D; Loda, M; Gopalan, A; Reuter, VE; Pritchard, CC; Mateo, J; Bianchini, D; Miranda, S; Carreira, S; Rescigno, P; Filipenko, J; Vinson, J; Montgomery, RB; Beltran, H; Heath, EI; Scher, HI; Kantoff, PW; Taplin, M-E; Schultz, N; deBono, JS; Demichelis, F; Nelson, PS; Rubin, MA; Chinnaiyan, AM; Sawyers, CL (2019-06-04)
      Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome. Here, ...
    • High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. 

      Perez-Lopez, R; Roda, D; Jimenez, B; Brown, J; Mateo, J; Carreira, S; Lopez, J; Banerji, U; Molife, LR; Koh, D-M; Kaye, SB; de Bono, JS; Tunariu, N; Yap, TA (2017-11-28)
      Despite impressive clinical activity in patients with germline BRCA1 and BRCA2 (BRCA1/2) mutant cancers, antitumor responses to poly(ADP-Ribose) polymerase (PARP) inhibitors are variable. We set out to assess the rate of ...
    • Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. 

      Nava Rodrigues, D; Rescigno, P; Liu, D; Yuan, W; Carreira, S; Lambros, MB; Seed, G; Mateo, J; Riisnaes, R; Mullane, S; Margolis, C; Miao, D; Miranda, S; Dolling, D; Clarke, M; Bertan, C; Crespo, M; Boysen, G; Ferreira, A; Sharp, A; Figueiredo, I; Keliher, D; Aldubayan, S; Burke, KP; Sumanasuriya, S; Fontes, MS; Bianchini, D; Zafeiriou, Z; Teixeira Mendes, LS; Mouw, K; Schweizer, MT; Pritchard, CC; Salipante, S; Taplin, M-E; Beltran, H; Rubin, MA; Cieslik, M; Robinson, D; Heath, E; Schultz, N; Armenia, J; Abida, W; Scher, H; Lord, C; D'Andrea, A; Sawyers, CL; Chinnaiyan, AM; Alimonti, A; Nelson, PS; Drake, CG; Van Allen, EM; de Bono, JS (2018-10-01)
      BACKGROUND: Understanding the integrated immunogenomic landscape of advanced prostate cancer (APC) could impact stratified treatment selection. METHODS: Defective mismatch repair (dMMR) status was determined by either loss ...
    • Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. 

      Pritchard, CC; Mateo, J; Walsh, MF; De Sarkar, N; Abida, W; Beltran, H; Garofalo, A; Gulati, R; Carreira, S; Eeles, R; Elemento, O; Rubin, MA; Robinson, D; Lonigro, R; Hussain, M; Chinnaiyan, A; Vinson, J; Filipenko, J; Garraway, L; Taplin, ME; AlDubayan, S; Han, GC; Beightol, M; Morrissey, C; Nghiem, B; Cheng, HH; Montgomery, B; Walsh, T; Casadei, S; Berger, M; Zhang, L; Zehir, A; Vijai, J; Scher, HI; Sawyers, C; Schultz, N; Kantoff, PW; Solit, D; Robson, M; Van Allen, EM; Offit, K; de Bono, J; Nelson, PS (2016-08)
      Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with localized prostate cancer ...
    • Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). 

      Mehra, N; Dolling, D; Sumanasuriya, S; Christova, R; Pope, L; Carreira, S; Seed, G; Yuan, W; Goodall, J; Hall, E; Flohr, P; Boysen, G; Bianchini, D; Sartor, O; Eisenberger, MA; Fizazi, K; Oudard, S; Chadjaa, M; Macé, S; de Bono, JS (2018-09)
      BACKGROUND: Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE: To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as ...
    • RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. 

      Nava Rodrigues, D; Casiraghi, N; Romanel, A; Crespo, M; Miranda, S; Rescigno, P; Figueiredo, I; Riisnaes, R; Carreira, S; Sumanasuriya, S; Gasperini, P; Sharp, A; Mateo, J; Makay, A; McNair, C; Schiewer, M; Knudsen, K; Boysen, G; Demichelis, F; de Bono, JS (2019-01-15)
      PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal but clinically heterogeneous disease, with patients having variable benefit from endocrine and cytotoxic treatments. Intrapatient genomic ...
    • Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. 

      Ferraldeschi, R; Welti, J; Powers, MV; Yuan, W; Smyth, T; Seed, G; Riisnaes, R; Hedayat, S; Wang, H; Crespo, M; Nava Rodrigues, D; Figueiredo, I; Miranda, S; Carreira, S; Lyons, JF; Sharp, S; Plymate, SR; Attard, G; Wallis, N; Workman, P; de Bono, JS (2016-05)
      Resistance to available hormone therapies in prostate cancer has been associated with alternative splicing of androgen receptor (AR) and specifically, the expression of truncated and constitutively active AR variant 7 ...
    • Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. 

      Lambros, MB; Seed, G; Sumanasuriya, S; Gil, V; Crespo, M; Fontes, M; Chandler, R; Mehra, N; Fowler, G; Ebbs, B; Flohr, P; Miranda, S; Yuan, W; Mackay, A; Ferreira, A; Pereira, R; Bertan, C; Figueiredo, I; Riisnaes, R; Rodrigues, DN; Sharp, A; Goodall, J; Boysen, G; Carreira, S; Bianchini, D; Rescigno, P; Zafeiriou, Z; Hunt, J; Moloney, D; Hamilton, L; Neves, RP; Swennenhuis, J; Andree, K; Stoecklein, NH; Terstappen, LWMM; de Bono, JS (2018-11-15)
      Purpose: Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency.Experimental Design: We evaluated liquid biopsies by apheresis to increase CTC yield from patients ...